REGENERON PHARMACEUTICALS, INC. Research and Development in Process
REGENERON PHARMACEUTICALS, INC. (REGN) reported Research and Development in Process of $195.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-06
- REGENERON PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. research and development in process for the quarter ending 2021-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. research and development in process for the quarter ending 2021-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. research and development in process for fiscal 2022 was $195.00M.
- REGENERON PHARMACEUTICALS, INC. research and development in process for fiscal 2021 was $0.00.
- REGENERON PHARMACEUTICALS, INC. research and development in process for fiscal 2020 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $0.00 derived: sum of 2 quarters · filed 2023-02-06 | $195.00M 10-K · filed 2023-02-06 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $195.00M 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $195.00M 10-Q · filed 2022-08-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $0.00 derived: sum of 2 quarters · filed 2023-02-06 | $0.00 10-K · filed 2023-02-06 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |